![Epigeneticists may be looking for epigenome-disease associations in the wrong place](https://cdn.cancerletter.com/media/2023/01/27151054/49-04-epigenetics-4x3-1.jpg)
![Epigeneticists may be looking for epigenome-disease associations in the wrong place](https://cdn.cancerletter.com/media/2023/01/27151054/49-04-epigenetics-4x3-1.jpg)
Cover Story
By Jacquelyn Cobb and Matthew Bin Han Ong
For a decade, thousands of PhDs in epigenetics may have been relying on the wrong tool as they study the biological processes that regulate how and when genes are expressed or silenced.
In Brief
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
![In Brief](https://cdn.cancerletter.com/media/2019/05/03155624/in-brief-3.jpg)
Clinical Roundup
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
![Clinical Roundup](https://cdn.cancerletter.com/media/2019/05/03161627/clinical_roundup.jpg)
Drugs & Targets
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
![Drugs & Targets](https://cdn.cancerletter.com/media/2019/05/03161633/targets2.jpg)
Trending Stories
- How a Georgetown med school student found her calling in surgery, law, and health equity
- Jeffrey S. Weber, pioneering immunologist and melanoma expert at NYU, dies at 72
- Laurie Glimcher to step down as Dana-Farber president and CEO, Benjamin Levine Ebert named successor
- Lei Zheng got his PhD in San Antonio; now he returns as cancer center director at Mays
- As NCI’s appropriations stay flat, Rathmell keeps the FY26 bypass budget steady at just under $11.5B
Rathmell: “We understand that there are real economic constraints facing our country and the world. But our gap just can’t keep widening.” - Huiping Liu discusses mentorship, translational research on the UChicago Cancer Luminaries podcast